123 related articles for article (PubMed ID: 37865189)
1. Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism.
Chen X; Lu T; Ding M; Cai Y; Yu Z; Zhou X; Wang X
J Adv Res; 2023 Oct; ():. PubMed ID: 37865189
[TBL] [Abstract][Full Text] [Related]
2. KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway.
Chen X; Lu T; Cai Y; Han Y; Ding M; Chu Y; Zhou X; Wang X
Cell Mol Biol Lett; 2023 Apr; 28(1):32. PubMed ID: 37076815
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2.
Xu R; Garcia-Barros M; Wen S; Li F; Lin CL; Hannun YA; Obeid LM; Mao C
Cell Death Differ; 2018 May; 25(5):841-856. PubMed ID: 29229990
[TBL] [Abstract][Full Text] [Related]
4. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
5. Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.
Zhang C; Sun Q; Zhang X; Qin N; Pu Z; Gu Y; Yan C; Zhu M; Dai J; Wang C; Li N; Jin G; Ma H; Hu Z; Zhang E; Tan F; Shen H
Cancer Commun (Lond); 2022 Jul; 42(7):609-626. PubMed ID: 35730068
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
7. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21
Liu R; Miao J; Jia Y; Kong G; Hong F; Li F; Zhai M; Zhang R; Liu J; Xu X; Wang T; Liu H; Hu J; Yang Y; He A
Oncogene; 2023 May; 42(20):1607-1619. PubMed ID: 37012388
[TBL] [Abstract][Full Text] [Related]
9. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
10. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
11. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.
Han H; Fan G; Song S; Jiang Y; Qian C; Zhang W; Su Q; Xue X; Zhuang W; Li B
Blood; 2021 Mar; 137(12):1603-1614. PubMed ID: 32967010
[TBL] [Abstract][Full Text] [Related]
12. METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer.
Zhan L; Zhang J; Zhang JH; Liu XJ; Guo B; Chen JH; Tang ZH; Wang WY; Wang QY; Wei B; Cao YX
Biomark Res; 2023 Apr; 11(1):43. PubMed ID: 37085864
[TBL] [Abstract][Full Text] [Related]
13. PA2G4 promotes the metastasis of hepatocellular carcinoma by stabilizing FYN mRNA in a YTHDF2-dependent manner.
Sun S; Liu Y; Zhou M; Wen J; Xue L; Han S; Liang J; Wang Y; Wei Y; Yu J; Long X; Chen X; Liang H; Huang Z; Zhang B
Cell Biosci; 2022 May; 12(1):55. PubMed ID: 35526051
[TBL] [Abstract][Full Text] [Related]
14. METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
Chen JX; Chen DM; Wang D; Xiao Y; Zhu S; Xu XL
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36960869
[TBL] [Abstract][Full Text] [Related]
15. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-145 Modulates
Yang Z; Li J; Feng G; Gao S; Wang Y; Zhang S; Liu Y; Ye L; Li Y; Zhang X
J Biol Chem; 2017 Mar; 292(9):3614-3623. PubMed ID: 28104805
[No Abstract] [Full Text] [Related]
17. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Zhang C; Huang S; Zhuang H; Ruan S; Zhou Z; Huang K; Ji F; Ma Z; Hou B; He X
Oncogene; 2020 Jun; 39(23):4507-4518. PubMed ID: 32366907
[TBL] [Abstract][Full Text] [Related]
18. FTO promotes the progression of retinoblastoma through YTHDF2-dependent N6-methyladenosine modification in E2F3.
Xie W; Shao Y; Bo Q; Li Z; Yu Q; Wang L; Wu G
Mol Carcinog; 2024 May; 63(5):926-937. PubMed ID: 38380957
[TBL] [Abstract][Full Text] [Related]
19. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
20. N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.
Miao YQ; Chen W; Zhou J; Shen Q; Sun Y; Li T; Wang SC
Bioengineered; 2022 Jan; 13(1):1858-1871. PubMed ID: 35012429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
